FOXO Technologies AI Stock Analysis
Want to see FOXO full AI Analyst Report?
FOXO Technologies (FOXO) AI Stock Analysis
FOXO Technologies
(Other OTC:FOXO)
The score is primarily held back by persistent losses and continued operating/free-cash-flow burn despite improving revenue and gross margin trends. Corporate events add mixed impact (operational progress but higher dilution risk), while valuation remains constrained by negative earnings and technicals cannot be substantiated from the missing indicator set.
FOXO Technologies (FOXO) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $1.69M
- Dividend Yield
- ―
- Average Volume (3M)
- 8,874
- Price to Earnings (P/E)
- 0.0
- Beta (1Y)
- 70.40
- Revenue Growth
- 44.03%
- EPS Growth
- ―
- Country
- US
- Employees
- 230
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Care Facilities
FOXO Technologies Business Overview & Revenue Model
Company Description
FOXO Technologies Inc. operates as a technology platform company primarily focused on translating longevity science into practical applications for the life insurance sector. The firm is actively creating products and services that integrate scientif...
How the Company Makes Money
FOXO Technologies generates revenue through a combination of direct-to-consumer sales and B2B partnerships. The company offers epigenetic testing services directly to consumers, allowing individuals to gain insights into their biological age and well...
FOXO Technologies Financial Statement Overview
Summary
Revenue growth and gross margin have improved, and leverage is meaningfully better (lower debt-to-equity and higher equity base). However, results are still dominated by large losses (deeply negative net margin) and ongoing cash burn with negative operating and free cash flow, keeping overall financial quality weak.
Income Statement
18Very NegativeBalance Sheet
42NeutralCash Flow
14Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 17.86M | 16.37M | 4.05M | 145.29K | 511.00K | 120.00K |
| Gross Profit | 8.48M | 8.04M | 1.57M | 12.86K | 167.00K | 120.00K |
| EBITDA | -327.21K | -8.60M | -7.28M | -24.11M | -92.30M | -37.27M |
| Net Income | -4.60M | -12.43M | -12.41M | -26.45M | -95.25M | -38.49M |
Balance Sheet | ||||||
| Total Assets | 45.89M | 44.58M | 41.71M | 725.00K | 35.41M | 30.30M |
| Cash, Cash Equivalents and Short-Term Investments | 58.41K | 207.45K | 68.27K | 38.00K | 5.51M | 6.86M |
| Total Debt | 20.65M | 10.97M | 14.25M | 4.20M | 3.14M | 32.20M |
| Total Liabilities | 44.98M | 33.50M | 36.44M | 14.82M | 28.70M | 55.52M |
| Stockholders Equity | 988.31K | 11.14M | 5.32M | -14.10M | 6.71M | -25.22M |
Cash Flow | ||||||
| Free Cash Flow | 208.69K | -3.93M | -2.84M | -6.64M | -25.63M | -15.30M |
| Operating Cash Flow | 355.81K | -3.87M | -2.84M | -6.64M | -23.76M | -15.05M |
| Investing Cash Flow | -650.08K | -655.61K | 13.33K | 0 | -1.87M | -355.00K |
| Financing Cash Flow | 814.74K | 4.66M | 2.86M | 1.17M | 24.29M | 14.14M |
FOXO Technologies Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FOXO, the sentiment is Positive. The current price of 0.17 is above the 20-day moving average (MA) of 0.12, above the 50-day MA of 0.12, and compared to the 200-day MA of , indicating a neutral trend. The MACD of 0.01 indicates Negative momentum. The RSI at 58.30 is Neutral, neither overbought nor oversold. The STOCH value of 94.83 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FOXO.
FOXO Technologies Risk Analysis
FOXO Technologies disclosed 65 risk factors in its most recent earnings report. FOXO Technologies reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksFOXO Technologies Peers Comparison
Overall Rating
BEAT47Neutral- FOXO45Neutral
VSEE41Neutral
HCTI38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| BEAT | 47Neutral | $23.01M | -0.79 | -686.78% | ― | ― | 26.80% |
| FOXO | 45Neutral | $315.04K | 0.03 | -43.80% | ― | 44.03% | ― |
| VSEE | 41Neutral | $564.25K | -0.03 | -400.87% | ― | -9.31% | 89.42% |
| HCTI | 38Underperform | $3.73M | -0.00 | -56.46% | ― | 116.40% | 99.31% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| FOXO | Foxo Technologies Inc. | 0.17 | -0.18 | -52.00% | |
| HCTI | Healthcare Triangle, Inc. | 4.39 | -2503.61 | -99.82% | |
| BEAT | Heartbeam, Inc. | 0.41 | -1.15 | -73.65% | |
| EUDA | Euda Health Holdings Limited | 15.65 | -43.55 | -73.56% | |
| VSEE | Vsee Health, Inc. | 0.69 | -58.65 | -98.84% | |
| BFRG | BullFrog AI Holdings, Inc. | 0.58 | -0.42 | -42.00% |
FOXO Technologies Corporate Events
FOXO Technologies expands rural care with new tele-specialties
PositiveOn January 18, 2026, FOXO Technologies increased its authorized common stock from 2.5 billion to 10 billion shares, a move that gives the company significantly more flexibility to raise capital, pursue corporate transactions, or support future growth...
FOXO Technologies Expands Share Authorization and Preferred Terms
PositiveOn December 16, 2025, FOXO Technologies amended the terms of its Series B and Series C cumulative convertible redeemable preferred stock, revising the conversion price formula to the higher of $0.0001 or 90% of the average volume-weighted average pri...
FOXO Technologies Announces Year-End Review by CEO
PositiveOn December 15, 2025, FOXO Technologies Inc. announced a year-end review by CEO Seamus Lagan, highlighting significant milestones and strategic acquisitions in 2025. The company expanded its healthcare portfolio by acquiring Myrtle Recovery Centers,...
FOXO Technologies’ Subsidiary Recognized for Community Impact
PositiveOn December 9, 2025, FOXO Technologies announced that its subsidiary, Myrtle Recovery Centers, was recognized by the Rural Health Association of Tennessee for its significant community impact. This recognition highlights Myrtle’s success in providing...
FOXO Technologies Amends Certificate for Preferred Stocks
NeutralOn October 29, 2025, FOXO Technologies Inc. amended its Certificate of Incorporation concerning its Series D and Series E Preferred Stocks. The amendment for Series D Preferred Stock revises the conversion price, while the Series E Preferred Stock am...
FOXO Technologies Increases Authorized Shares Significantly
NeutralFOXO Technologies Inc., a Delaware corporation, has increased its authorized shares of Common Stock from 500,000,000 to 2,500,000,000 shares. This amendment to the Certificate of Incorporation was filed with the Secretary of State of Delaware and bec...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Jan 20, 2026